Vivasure Medical Receives €30M Investment from Haemonetics

Funding Rounds

▤ Summary

Vivasure Medical, a Galway, Ireland-based company focused on absorbable technology for percutaneous vessel closure, received a €30m strategic investment from Haemonetics Corporation (NYSE: HAE) as part of its previously disclosed Series D financing. The company intends to use the clinical study results to support an FDA pre-market approval submission as well as multinational commercial launch of the PerQseal system for large hole vessel closure. PerQseal is designed to be the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures. Its low profile patch can be placed from inside the vessel and is intended to make deployment simpler and more controlled than conventional closure techniques. The company operates a fully integrated R&D and ISO 13485 certified manufacturing facility and is backed by leading international medtech investors.

$ Funding

$
Amount - Total raised
□
Date - Announcement date
◎
Investors Haemonetics Lead investors
▥
Company - Funded company

▥ Classifications

industries
HealthTech
applications
Accounting and Taxes

◇ AskAI Classifications

Labels
Medical Device Software Healthcare IT Clinical Workflow Software

▦ Linked Companies